Turning Firsts Into What’s Next [STAT Summit 2026 Review #28]

Report 28. Turning Firsts Into What’s Next

Part I. English Version

1. Event / Date & Time

Event: Turning Firsts Into What’s Next | Sponsored by Children’s Hospital of Philadelphia

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 12:10 PM EDT

2. Participants

Speakers

- Tom Wilton — Senior Vice President, Innovation Ventures, Children’s Hospital of Philadelphia (CHOP)

Moderator

- Gideon Gil — Managing Editor, STAT

3. Summary

Pediatric Translational Innovation: CHOP described how pioneering cell and gene therapies can become a foundation for broader clinical and commercial development.

Institutional Commercialization: A centralized Innovation Ventures function is intended to connect research, intellectual property and industry partnerships earlier in development.

Infrastructure and Partnerships: Pediatric biobanks, manufacturing capacity and clinical data can support collaboration on new therapies, diagnostics and AI applications.

4. Main Discussion

A Record of Pediatric Firsts

Wilton reviewed CHOP’s legacy of vaccine and surgical innovations and highlighted recent milestones such as CAR-T therapy Kymriah, inherited-retinal-disease gene therapy Luxturna, and a personalized gene-editing treatment for a child known as “baby KJ.” These examples illustrated a continuum from academic discovery to first-in-patient interventions.

Wilton described a long institutional lineage of clinical and technical firsts, from vaccination and neonatal care to newer advanced therapies. In collaboration with the University of Pennsylvania, CHOP was involved in CAR-T development associated with Kymriah and in the development of Luxturna for inherited retinal disease. He also highlighted an individualized gene-editing intervention for an infant publicly known as baby KJ. These examples differ in mechanism and maturity, but they share a translational challenge: specialized work conducted around a single patient or academic center must eventually become reproducible, clinically reliable and accessible to more people. The session highlighted pioneering care without claiming that every individualized intervention is already scalable or approved.

Wilton situated CHOP’s current commercialization ambitions in a history of pediatric medical firsts. He cited early vaccine research, advances in neonatal and transplantation care, and more recent work with the University of Pennsylvania leading to the CAR-T therapy Kymriah and the gene therapy Luxturna. He also discussed the individually designed gene-editing treatment given to a child identified as baby KJ. These examples span very different modalities, but share dependence on close interaction among clinicians, researchers, manufacturing specialists and regulators. For a pediatric hospital, the pathway from discovery to treatment may be especially demanding because patient populations are small and individualized approaches challenge conventional development economics.

Scale of the Research Enterprise

According to Wilton, CHOP has more than 1,000 principal investigators and over $500 million in annual research funding. He cited a large pediatric biobank, GMP manufacturing, animal-model facilities and extensive omics and electronic health-record data as assets for translational work.

The scale of CHOP’s translational resources was central to its value proposition. Wilton cited more than 1,000 principal investigators and more than $500 million in annual research funding, together with a major pediatric biobank, GMP manufacturing and preclinical facilities. Such assets support the movement from biological discoveries to evidence packages that external partners can evaluate. For pediatric and rare conditions, the available patient population may be very small, which increases the importance of well-characterized samples and coordinated clinical data. Wilton argued that the combination of patient care, long-term records and laboratory resources creates a research setting difficult to reproduce within a standalone startup. The numbers were presented by the institution’s representative during the session.

The speaker described a substantial institutional research base rather than a small technology-transfer office. CHOP’s infrastructure includes more than 1,000 principal investigators, annual research funding exceeding $500 million, a pediatric biobank, GMP manufacturing resources and preclinical facilities. Such assets give the hospital options for following a discovery into translational work without immediately relying on an external company at every step. But their breadth also creates fragmentation: researchers and outside partners need a clear way to identify which expertise, material or support can advance a project. The innovation organization was presented as a response to this coordination problem, not simply a mechanism for licensing patents.

One Entry Point for Commercialization

CHOP’s Innovation Ventures unit aims to offer industry a coordinated entry point for licensing and co-development. Wilton emphasized engaging earlier in product design to consider regulatory, commercial and manufacturing requirements before technologies reach advanced trials. He noted that academic hospitals can conduct early studies but usually need partners to scale products.

CHOP’s Innovation Ventures function was framed as a bridge between academic discovery and external product development. Wilton had worked in biopharma for roughly 25 years, including about 12 years in cell and gene therapies, before moving into the hospital environment. He argued that successful commercialization requires early consideration of intellectual property, product design, manufacturing, clinical evidence and regulatory pathways. A centralized function gives partners a clearer route into a large research institution rather than forcing every laboratory to independently negotiate the entire process. The model recognizes that hospitals can undertake discovery and initial patient studies but generally need specialized industry partners to manufacture, finance and distribute therapies at greater scale.

The baby KJ case provided a concentrated example of coordinated translation. The discussion highlighted the rapid sequence from identifying a patient’s unique genetic problem through therapeutic design, preclinical work, authorization to treat and bedside delivery. It did not imply that every single-patient therapy can follow the same timeline or that the regulatory obstacles have disappeared. Instead, the case illustrated why integrated hospital capacity can be valuable when clinical urgency is high. For future programs, manufacturing readiness, regulatory communication, genomic data, intellectual-property arrangements and patient follow-up all need to be built into the project from its earliest stages.

Next-Generation Data and AI Collaboration

Wilton also identified opportunities to link CHOP’s pediatric clinical and molecular data with advanced analytics developers. Potential applications include new therapeutics, diagnostics and improved care processes, provided that partner capabilities complement clinical expertise.

Wilton connected the baby KJ case to a broader aspiration for rare-disease treatment. He noted that there are about 10,000 rare diseases and relatively few established treatments, raising the question of whether personalized development could someday become faster and more systematic. He did not suggest that every disorder can now receive a bespoke intervention; instead, he described the potential for reusable technical and institutional infrastructure to reduce the work required for subsequent cases. Coordinated laboratory methods, GMP systems, regulatory learning and data capabilities could make future projects more feasible than one-off demonstrations. The central strategic issue is how to preserve rigorous evidence and safety standards while shortening the path from a molecular diagnosis to an intervention.

Wilton’s experience in biopharma informed his view that hospitals can become more active partners in company formation and therapeutic development. A discovery emerging from a hospital laboratory often needs financing, product-development planning and commercial capabilities that research grants were not intended to provide. A coordinated entry point for industry can make collaboration more legible and identify projects suited to different partnership models. The industrial promise is substantial, but the session did not present a quantitative return on CHOP’s innovation program. It emphasized building a repeatable pathway for difficult pediatric discoveries rather than treating each success as a one-off exception.

5. Insights

Translation Infrastructure: Dedicated commercialization capacity can help convert high-value academic research into scalable pediatric treatments.

Implications for South Korea: Korea could consider integrating pediatric research assets, GMP capabilities and technology-transfer support in translational programs.

Clinical–Industry Partnerships: Earlier co-development with manufacturers and data companies may help advance innovative treatments beyond single-center demonstrations.

Report 28. Turning Firsts Into What’s Next_eng.pdf

Download PDF • 68KB